JP2009502914A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502914A5
JP2009502914A5 JP2008523847A JP2008523847A JP2009502914A5 JP 2009502914 A5 JP2009502914 A5 JP 2009502914A5 JP 2008523847 A JP2008523847 A JP 2008523847A JP 2008523847 A JP2008523847 A JP 2008523847A JP 2009502914 A5 JP2009502914 A5 JP 2009502914A5
Authority
JP
Japan
Prior art keywords
disorders
withdrawal
substance
withdrawal symptoms
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008523847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502914A (ja
JP5094720B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/026439 external-priority patent/WO2007018496A1/en
Publication of JP2009502914A publication Critical patent/JP2009502914A/ja
Publication of JP2009502914A5 publication Critical patent/JP2009502914A5/ja
Application granted granted Critical
Publication of JP5094720B2 publication Critical patent/JP5094720B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008523847A 2005-07-26 2005-07-26 サブスタンス関連障害を処置する方法 Expired - Fee Related JP5094720B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/026439 WO2007018496A1 (en) 2005-07-26 2005-07-26 Methods for treating substance-related disorders

Publications (3)

Publication Number Publication Date
JP2009502914A JP2009502914A (ja) 2009-01-29
JP2009502914A5 true JP2009502914A5 (enExample) 2012-03-29
JP5094720B2 JP5094720B2 (ja) 2012-12-12

Family

ID=35064669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008523847A Expired - Fee Related JP5094720B2 (ja) 2005-07-26 2005-07-26 サブスタンス関連障害を処置する方法

Country Status (13)

Country Link
EP (1) EP1928451B1 (enExample)
JP (1) JP5094720B2 (enExample)
KR (1) KR101199499B1 (enExample)
CN (1) CN101272776B (enExample)
AT (1) ATE538784T1 (enExample)
AU (1) AU2005335241B9 (enExample)
BR (1) BRPI0520451A2 (enExample)
CA (1) CA2616721C (enExample)
EA (1) EA019935B1 (enExample)
ES (1) ES2385087T3 (enExample)
IL (1) IL189003A0 (enExample)
NO (1) NO20080877L (enExample)
WO (1) WO2007018496A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
RU2557533C2 (ru) 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
BR112015022197B1 (pt) 2013-03-13 2022-06-07 Sk Biopharmaceuticals Co., Ltd. Uso de um composto para o tratamento de cataplexia
CN105873576B (zh) 2013-07-18 2019-07-19 爵士制药国际Iii有限公司 治疗肥胖
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR20240162165A (ko) 2017-06-02 2024-11-14 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
JP7257091B2 (ja) * 2019-06-27 2023-04-13 沼澤 敏彦 認知症の治療及び予防薬
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
KR100886578B1 (ko) * 2001-02-27 2009-03-05 오르토-맥네일 파마슈티칼, 인코퍼레이티드 카바메이트 화합물을 포함하는 정신증 장애 예방용 또는 치료용 약제학적 조성물
BR0207832A (pt) * 2001-02-27 2004-06-22 Ortho Mcneil Pharm Inc Compostos de carbamato para uso na prevenção ou tratamento de distúrbio bipolar
ATE369130T1 (de) * 2001-02-27 2007-08-15 Ortho Mcneil Pharm Inc Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
PT1383489E (pt) * 2001-02-27 2007-06-21 Ortho Mcneil Pharm Inc Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Similar Documents

Publication Publication Date Title
JP2009502914A5 (enExample)
Dome et al. Smoking, nicotine and neuropsychiatric disorders
Kumru et al. Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations
Mahowald et al. Parasomnias
Angelucci et al. Investigating the neurobiology of music: brain-derived neurotrophic factor modulation in the hippocampus of young adult mice
Hassan et al. Novel psychoactive substances—recent progress on neuropharmacological mechanisms of action for selected drugs
JP2019031502A5 (enExample)
JP2008534627A5 (enExample)
JP6421185B2 (ja) ベンゾイミダゾール−プロリン誘導体の使用
AU2021206771B2 (en) Cognitive disorder prevention and therapy
JP2017535612A5 (enExample)
JP2005523335A5 (enExample)
WO2008048410A3 (en) Diagnostic methods and genetic markers for alzheimer disease
Niaura et al. Varenicline
CN117500788A (zh) 作为血清素能药物的用于治疗与之相关的疾病的吲哚衍生物
Szily et al. Designer drugs in psychiatric practice-a review of the literature and the recent situation in Hungary
EA200601611A1 (ru) Терапия с применением производных 1-аминоциклогексана для лечения поведенческих нарушений, ассоциированных с болезнью альцгеймера
Manconi et al. Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome
Taba et al. Erich Harnack (1852–1915) and a short history of apomorphine
Breuer et al. “Herbal seizures”–atypical symptoms after ibogaine intoxication: a case report
Bin et al. Preliminary evaluation of the efficacy and safety of brimonidine for general anesthesia
JP2008526706A5 (enExample)
JP2010505919A5 (enExample)
JP2006519251A5 (enExample)
Patel et al. Effect of Alcohol on Brain Development